The global head and neck squamous cell carcinoma market is set for steady growth, driven by advancements in treatment options, increasing awareness of early cancer detection, and rising demand for ...

The European Commission has approved Libtayo (cemiplimab) as the first and only immunotherapy for adult patients with ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free ...

DPI-4452 targets CAIX in tumors, offering noninvasive diagnostic potential for ccRCC with favorable tolerability. The agent is part of a theranostic pair wi ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...

CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company pioneering a novel gene editing platform to overcome drug resistance in solid tumors, today announced the publication of a ...

The oropharyngeal cancer market is anticipated to grow during the forecast period (2025--2034), driven by the launch of emerging therapies such as PDS Biotechnology's Versamune HPV, Inovio ...

Researchers at the School of Dentistry at UT Health San Antonio, the academic health center of The University of Texas at San Antonio, have been awarded three multi-year grants totaling $6 million ...

Artificial neural networks predicted overall and progression-free survival after chemoradiation in older adults with head and ...

That stubborn spot on your face that refuses to go away may just not be that usual pimple, after all. Every year, millions ...

Germany's Merck KGgA said on Monday it has agreed to pay Swiss biotech Debiopharm up to 900 million euros ($1.08 billion) to ...